1. Home
  2. AER vs RPRX Comparison

AER vs RPRX Comparison

Compare AER & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerCap Holdings N.V.

AER

AerCap Holdings N.V.

N/A

Current Price

$136.58

Market Cap

21.4B

ML Signal

N/A

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

N/A

Current Price

$45.61

Market Cap

19.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AER
RPRX
Founded
1995
1996
Country
Ireland
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.4B
19.7B
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
AER
RPRX
Price
$136.58
$45.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
$150.29
$47.75
AVG Volume (30 Days)
1.4M
2.9M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
1.22%
2.07%
EPS Growth
N/A
N/A
EPS
N/A
1.78
Revenue
N/A
$2,378,193,000.00
Revenue This Year
N/A
$38.30
Revenue Next Year
$1.53
$4.80
P/E Ratio
$7.27
$25.45
Revenue Growth
N/A
5.06
52 Week Low
$85.57
$29.66
52 Week High
$154.94
$47.86

Technical Indicators

Market Signals
Indicator
AER
RPRX
Relative Strength Index (RSI) 43.80 53.21
Support Level $130.97 $44.94
Resistance Level $138.34 $46.14
Average True Range (ATR) 4.24 0.83
MACD -0.44 -0.24
Stochastic Oscillator 29.90 35.28

Price Performance

Historical Comparison
AER
RPRX

About AER AerCap Holdings N.V.

AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. It has one business segment: leasing, financing, sales, and management of commercial flight equipment (Commercial Flight Equipment Segment). Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, the United States, and Other countries.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: